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Abstract
Purpose Acromegaly has high morbidity and mortality when growth hormone secretion remains uncontrolled. Stereotactic 
radiosurgery (SRS) may be used when pituitary surgery is not suitable or unsuccessful, but there are few very long-term 
safety data available, especially for significant adverse events such as stroke.
Methods 118 patients with acromegaly were treated with SRS between 1985 and 2015, at the National Centre for Stereotactic 
Radiosurgery, Sheffield, UK. Data were gathered from case notes, hospital databases, and patient questionnaires. Stroke 
incidence in comparison to the normal population was quantified using the standardised incidence ratio (SIR), and visual 
complications assessed.
Results 88% (104/118) had complete morbidity follow up data for analysis. The mean follow-up was 134 months, and median 
SRS dose was 30 Gy. 81% of tumours had cavernous sinus invasion. There was no excess stroke rate relative to that seen in 
two age- and sex-matched large population studies (SIR = 1.36, 95% CI 0.27–3.96; SIR = 0.52, 95% CI 0.06–1.89). In 68/104 
patients who had MRI-guided SRS with no further radiation treatment (SRS or fractionated radiotherapy) there was no loss 
of visual acuity and 3% developed ophthalmoplegia. There was a positive correlation between > 1 radiation treatment and 
both ophthalmoplegia and worsening visual acuity.
Conclusion Stroke rate is not increased by SRS for acromegaly. Accurate MRI-based treatment planning and single SRS 
treatment allow the lowest complication rates. More than one radiation treatment (SRS or fractionated radiotherapy) was 
associated with increased visual complications.
Keywords Acromegaly · Hypopituitarism · Pituitary adenoma · Radiation · Radiosurgery · Fractionated radiotherapy · 
Stroke · Transient ischaemic attacks · Morbidity · Mortality · Complications · Safety
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Introduction
Uncontrolled acromegaly results in a three-fold increase in 
all-cause mortality which is reversible with normalisation of 
GH and IGH-1 levels [1–3]. Untreated acromegaly is associ-
ated with diabetes mellitus, hypertension, cardiomyopathy, 
obstructive sleep apnoea and increased risk of colorectal 
carcinoma [2]. Pituitary surgery is the recommended first 
line treatment for acromegaly [3, 4] and achieves immediate 
tumour and biochemical control in 65% of patients (45–64% 
of patients with macroadenomas and in 72–90% with micro-
adenomas) [3–6]. Where surgery does not achieve complete 
remission or is contra-indicated, primary medical manage-
ment can achieve biochemical control in up to 50% [3, 6]. In 
cases of inadequate control or poorly tolerated side effects 
using medication, fractionated radiotherapy (RT) (multiple 
low radiation doses over several weeks) or stereotactic radio-
surgery (SRS) (high dose radiation using multiple axes of 
delivery) are established treatments that control tumour size 
and GH secretion [3, 4, 7]. Radiotherapy is, however, an 
independent risk factor for increased mortality [5, 8]. This 
increased mortality rate may not apply to SRS [3].
For acromegaly, SRS is the recommended form of radia-
tion [3, 4, 9]. SRS offers endocrine remission in 40–60% 
of patients at 5–10 years and control of tumour growth in 
93–100% [10]. SRS is thought to offer a more favourable 
side effect profile than RT [3, 9, 11], by minimising the radi-
ation dose to normal tissue. The lack of effect on normal 
tissues is illustrated by the fact that in contrast to RT, SRS 
does not result in increased risk of secondary brain tumours 
[12, 13], but other non-endocrine complications including 
ophthalmoplegia, visual loss and trigeminal nerve dysfunc-
tion appear to relate to the region treated [9, 14, 15].
One specific concern about all forms of cranial radiation 
is the potential for long term cerebrovascular damage and 
stroke. Data on stroke following RT for pituitary tumours 
suggest an increased risk in some [1, 5, 16, 17], but not all 
series [12, 18, 19]. At the National Centre for Stereotactic 
Radiosurgery, Sheffield, UK we have used the gamma knife 
to deliver SRS to over 360 patients with pituitary disease 
over the last 35 years. Here, we present unique long-term 
data on 118 patients with acromegaly to assess stroke risk 
and safety of this treatment.
Methods
Radiosurgical technique
The use of the Leksell gamma knife (Elekta, Sweden) for 
the treatment of tumours has been well described [20]. 
13 early patients were localised with CT, but since 1993 
the subsequent 91 treatments were all based upon gado-
linium enhanced T1 weighted volumetric MRI scans and 
planned with multiple isocentres mean 7 (range 1–21) 
using GammaPlan (Elekta AB, Sweden) (Table 1). Prior 
to 2011 cases were treated on the Gammaknife Model C 
following which all cases were treated on the Gammaknife 
Perfexion model. Median and mean isocontour of 50% 
(range 45–60%) was matched to the margin of the tumour 
and used to deliver a mean marginal dose of 28.0 Gy (Gy) 
(range 17.2–38.0) whilst maintaining a dose of ≤ 8 Gy to 
the optic apparatus. A maximum dose threshold was not 
applied to the cavernous sinus as the majority of tumours 
requiring treatment were within this area; opthalmoplegia 
incidence from SRS in our centre is low [21]. The mean 
treatment volume was 1949  cm3 (range 88–3938).
Data collection
We performed a retrospective review of 118 patients 
undergoing gamma knife treatment for acromegaly 
between 1985 and 2015 at the National Centre for Stereo-
tactic Radiosurgery, Sheffield, UK. In our role as national 
centre, patients are followed up for biochemical remission 
and complications by their local endocrinology service. 
Biochemical testing was performed at regional testing cen-
tres and results were not available to the authors of this 
study. At the time of referral patients had uncontrolled 
GH levels as determined by their regional endocrinol-
ogy service. They were then considered by the Sheffield 
SRS-Pituitary MDT prior to being counselled with regard 
to their treatment options. Given the variation in assays, 
normal ranges and criteria for control over this long time 
period, it is not possible to quantify comparative disease 
burden at the time of treatment. Our study focussed on 
associated mortality and morbidity from SRS. Complica-
tion data however was available from clinic letters and via 
patient outcome survey to ensure quality of service pro-
vision. To mitigate against incongruent or missing clini-
cal information, patients and general (family) praction-
ers (GPs) were contacted directly to confirm or fill gaps 
of knowledge using a patient specific questionnaire (see 
appendix II). Pituitary function was inferred from the use 
of pituitary replacement therapy as directed by regional 
endocrinologists. Premorbid state of patients undergoing 
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SRS was obtained from clinic letters or pre-SRS clini-
cal assessment. Mortality was confirmed on The National 
Health Service (NHS) patient database and death certifi-
cates reviewed to find causality relating to SRS.
Statistical methods
Overall survival was calculated as the time elapsed between 
first SRS treatment and death. Where death had not occurred, 
patients were censored at the last follow-up review (data col-
lection completed in April 2018).
Due to retrospective data collection the exact date of new 
morbidity was not always available. Rules for generating an 
exact date for complication onset were applied uniformly.
The incidence of first stroke in comparison to the nor-
mal population was quantified using age-and-sex-matched 
incidence data. The incidence of strokes observed among 
patients in the gamma knife cohort was compared against 
two large population studies:
Table 1  Comparison of patient characteristics between those included in follow-up and those excluded due to inadequate data
*Data for two tumour volumes were estimated from their known treatment volume
# Qscores provided for 113 of 118 patients; unable to perform on patients aged less than 25 [25]
Characteristic Cohort Lost to follow-up
Sample size (n) 104 14
Male:female 55:49 10:4
Median Follow up in months (range) 107 (18–362) –
Median age at SRS 45 46
Median surgeries @ time of SRS (range) 1 (0–3) 1 (0–3)
Median (range) marginal dose 30 Gy (17.2–38) 25 Gy (20–35)
Mean (median) tumour volume  (cm3) 1934 (972)* 1776 (985)
Mean (median) treatment volume  (cm3) 1949 (1100) 2002 (1015)
Planning modality (MRI:CT) 91:13 13:1
Cavernous sinus invasion (%) 81% (84/104) 93% (13/14)
Fractionated radiotherapy (RT) prior to SRS 25% (26/104) 36% (5/14 patients in 
whom data avail-
able)
Co-morbidities at time of SRS
 ASA 3 or 4 20.2% (21/104) 21.4% (3/14)
 Diabetes mellitus 10.6% (11/104) 14.3% (2/14)
 Sleep apnoea 5.8% (6/104) 14.3% (2/14)
 Valvular heart disease 3.9% (4/104) 0%
 HTN 9.6% (10/104) 14.3% (2/14)
#Q-stroke score (10 year risk) Mean (Median) 2.5% (0.8%) 2.2% (0.8%)
Deaths (median age at death in years) 13 (67) 5 (62)
Median time to death from SRS in month (range) 102 (18–243) –
Cause of death Cardiac (3) Unavailable
 - Tachyarrhythmia
 - Left ventricular failure
 - Acute pulmonary oedema secondary to AF
Respiratory(2)








 - Metastatic cancer (unknown primary)
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(1) The Oxford Vascular study assessed stroke incidence 
in 90,000 people, selected by registration with a fam-
ily physician in the defined area. The sample was 91% 
white and represented a higher than average median 
economic status; as our cohort are also from the UK, 
this was our primary reference population [22].
(2) The City of Copenhagen population registry reported 
stroke incidence from a random sample of 19,698 
patients taken from a population of 87,172 people, all 
of whom were older than 20 years; this was used to 
check the sensitivity of findings to a different reference 
population [23]. The City of Copenhagen study did not 
include transient ischaemic attacks (TIAs) in its defini-
tion of stroke and instances of TIA were removed from 
this comparison.
Both studies reported first stroke incidence by sex and 
10-year age strata, enabling us to calculate the expected 
number of strokes over each patient’s follow-up time more 
accurately than overall population figures (see appendix for 
details). Person-years were defined as the duration from the 
date of first SRS to the date of stroke, date of death or date of 
record retrieval. 95% confidence intervals for the SIR were 
derived as described in Breslow and Day [24]. Factors asso-
ciated with speed to remission, development of hypopituita-
rism, cerebrovascular events and other known complications 
were assessed by univariate analysis. Kaplan–Meier plots 
were performed to demonstrate the temporal association of 
developing hypocortisolism, hypogonadism and hypothy-
roidism. Those who were pan-hypopituitary pre-SRS were 
excluded from this specific analysis. A separate analysis 
was performed for those who had intact pituitary function 
pre-SRS. Two-sided Fisher’s exact tests were used to assess 




118 patients were treated using the gamma knife for acro-
megaly between 1985 and 2015, of whom detailed medical 
records were obtained for 104; a comparison of those with 
and without full data is provided in Fig. 1 and Table 1. Mean 
follow up was 134 months (median 107; range 18–362). In 
the MRI guided subgroup (n = 91) the mean follow up was 
117 (median 96) months from SRS treatment. The number 
of patients not prescribed medication to control GH at last 
follow up halved relative to pre-SRS prescriptions (Supple-
mentary table IIa) and the full range of therapies to control 
GH also reduced (Supplementary table IIb). Due to the com-
plexity of treatment pathways a summary of non-endocrine 
morbidity as they relate to prior treatment is demonstrated 
in a flow diagram (Fig. 2). 
Fig. 1  Flow diagram of 
included patients in study. 
+In the MRI guided subgroup 
(n = 91) the mean follow up was 





Cause of death was ascertained for 18 of the 19 patients who 
had died. Median time to death post SRS was 102 months 
(range 18–243). No death was related to SRS treatment, but 
all deaths were attributable in part to the underlying diag-
nosis of acromegaly (Table 1).
Non‑endocrine morbidity
Stroke
Our cohort had a mean QRisk score [25] (10 year risk of 
stroke) of 2.3%; and considerably higher than average rates 
of hypertension, diabetes mellitus and valvular heart disease. 
Despite this, there was no increased risk of stroke relative to 
population studies. In total there were two Transient Ischae-
mic Accidents (TIAs) and two strokes in 3 patients which 
occurred at 3.9 years, 6.4 years, 6.9 and 8.7 years after SRS. 
The three affected patients all had MRI-guided SRS; two 
had cavernous sinus invasion; one had prior fractionated 
radiotherapy (Table 2). The remaining 101 patients were 
followed up between 1.6 and 30.2 years (mean 11.3 years). 
The expected incidence of first stroke based on the Oxford 
cohort population figures [22] was 2.21, giving a SIR of 1.36 
(95% CI 0.27 to 3.96); in absolute terms, an extra 0.7 strokes 
per 1000 person-years. By contrast, fewer strokes (exclud-
ing TIAs) than expected were observed when standardising 
against the Copenhagen cohort [23] (expected number 3.83, 
SIR = 0.52, 95% CI 0.06 to 1.89) (see Appendix).
Visual and cavernous sinus‑related morbidity
A total of 26 non-endocrine complications affecting 22 
patients occurred, making an incidence per patient year of 
0.002. Further reduction in complication rates occurred with 
transition to MRI-guided SRS (n = 91) (Tables 2 and 3).
Fig. 2  Summary of differing treatments received by the patients, pre and post stereotactic radiosurgery (SRS), and their relevant non-endocrine 







Table 2  Summary of patients who developed non-endocrine morbidity after SRS
Deficit Description of symp-
toms (where available)
Date of SRS Onset 
post SRS 
(months)










Date of TSPS Date of RT Total radia-
tion treat-
ments
Loss of acuity Rapid visual loss 
post SRS; Imaging 
showed lesion on 
optic nerve. This 
was biopsied and 






8 25 493 CT 0 No N/A n/a 1
Loss of acuity Visual deterioration 
14 months after 
SRS. Registered as 




14 20 851 CT 1 No 1987 n/a 1
Loss of acuity Left eye vision has 
deteriorated (but 
still functional); 




n/a 20 5600 MRI 1 Yes 21/07/1996 01 October 
1996
2
Loss of acuity Documentation in 
notes of visual 
deterioration; patient 
had died at time of 





5 25 851 CT 1 No 1983 05 April 1983 2
Loss of acuity Right eye blindness 09/07/1993 
& 26 May 
2004
105 30 2700 CT + MRI 
guided
1 Yes (2004) 1989 1990 3
Loss of acuity Progressive loss of 
vision started 1 year 
post and progressed 
for 10 years. On 
review by SRS team 
at Sheffield; clinic 
letters support a 
diagnosis of SRS 




12 30 2300 MRI 2 Yes 1999—diagno-
sis + TSPS; 
2000 TSPS
01 June 2000 2
Ophthalmo-
plegia
Right CN3 palsy 24 February 
2010








Table 2  (continued)
Deficit Description of symp-
toms (where available)
Date of SRS Onset 
post SRS 
(months)
























18 June 2012 n/a 20 5830 MRI 1 Yes 01/11/2011 n/a 1
Ophthalmo-
plegia
Left CN3 palsy 30 October 
2013
26 30 12,960 MRI 3 Yes 2009, 2009, 
2010 April
01 July 2010 2
Opthalmople-
gia
n/a 10 August 
2005
24 30 2300 MRI 2 Yes 1999 TSPS; 
2000 TSPS
01 June 2000 2
Opthalmople-
gia
Left CN3 palsy 27 November 
2012
2 25 11,110 MRI 1 Yes 24/01/2012 n/a 1
Opthalmople-
gia
Left CN3 palsy 06 November 
2013
n/a 30 1890 MRI 1 Yes 01/12/2009 06/11/2010 2
Trigeminal 
neuralgia




0.1 (4 days) 30 2300 MRI 2 Yes 1999—diagno-
sis + TSPS; 
2000 TSPS
01 June 2000 2






83 30 555.9 MRI 1 No 01/11/2003 n/a 1
TIA 01/08/2012 (TIA—no 
sustained neuro-
logical deficit; had 
incompetent heart 
valves); subse-
quently put on War-
farin & underwent 




84 30 2300 MRI 2 Yes 1999—diagno-
sis + TSPS; 
2000 TSPS
01 June 2000 2
CVA TIA 
28/05/2009 + Stroke 
16/03/2014 (anterior 
circulation / leg 
affected); smoker
29 June 2005 47 30 1500 MRI 1 Yes 2004 n/a 1




























Table 2  (continued)
Deficit Description of symp-
toms (where available)
Date of SRS Onset 
post SRS 
(months)










Date of TSPS Date of RT Total radia-
tion treat-
ments
Need for post 
SRS TSPS
TSPS 1999; SRS 
2002; further TSPS 
2004











18 35 1000 MRI 1 No 01 June 2011 n/a 1
Need for post 
SRS TSPS
TSPS 1986; SRS 




48 20 493 CT 2 Yes 1986, 1991 30 January 
1987
2
Need for post 
SRS TSPS
TSPS 2009; SRS 
2011; further TSPS 
2012
01 June 2011 18 30 2700 MRI 2 Yes 07/2009, 
12/2012
n/a 1
Need for post 
SRS Radia-
tion
TSPS 2005; SRS 
2006; SRS 2013
05 July 2006 
& 16 Janu-
ary 2013
78 30 + 30 677.9 MRI 1 Yes (left 
2006)
10/11/2005 n/a 2
Need for post 
SRS Radia-
tion
TSPS 1989; SRS 
1993; SRS 2004
09 July 1993 
& 26 May 
2004
130 30 + 30 2700 MRI 1 Yes (right 
2004)
1989 1990 3
Need for post 
SRS Radia-
tion
TSPS 2004; SRS 
2005; RT 2010






In 84/104 patients there was cavernous sinus invasion. 
Of these 84 there were seven cases of ophthalmoplegia; 
all cases had MRI-guided treatment, targeting of the cav-
ernous sinus due to tumour invasion, and had had prior 
pituitary surgery. Two of 68 patients receiving only MRI-
guided SRS, and no other pituitary radiation, developed 
opthalmoplegia. Univariate analysis found > 1 radiation 
treatment to be a significant association with the occur-
rence of ophthalmoplegia (p = 0.03; Fisher’s exact two-
tailed) giving an Odds ratio of 6.6(95% CI 1.2–34).
In the 68 receiving a single MRI-guided SRS treatment 
and no other cranial radiotherapy, there were no cases of 
visual loss. Overall, there were six cases of reduced visual 
acuity. Of these, four had undergone CT-guided treatment 
(historical mode of targeting prior to MRI being available), 
and two had had MRI-guided treatment and more than 
one radiation treatment. In the CT-guided treatment group 
31% (4/13) developed loss of acuity, whereas 2.1% (2/91) 
developed reduced acuity after MRI-guided SRS and other 
pituitary radiation. CT-guided treatment was significantly 
associated with loss of visual acuity (p = 0.008; Fisher’s 
exact test, two-tailed), odds ratio 17.6 (95% 3.5–96.1). 
Repeat radiation treatment (of any type) was associated 
with reduced visual acuity (p = 0.04; Fisher’s exact test, 
two-tailed) with odds ratio of 6.5 (95% 1.4–35.2).
Visual complications were also associated with the 
number of interventions (i.e. surgery/radiation) undertaken 
to achieve growth hormone control, irrespective of treat-
ment modality (Supplementary table I; p = 0.0001). There 
was an isolated case of trigeminal neuralgia in a patient 
who had MRI-guided SRS five years after fractionated 
radiotherapy.
Hypopituitarism
Forty-three (41%) of the 104 patients had abnormal pituitary 
function prior to SRS treatment. Seven out of 104 patients 
required hormone replacement in 3 axes (thyroxine/cortisol/
sex hormones) prior to treatment. In the remaining ninety-
seven patients, 34 (38%) developed a new deficit in at least 
one axis after SRS. Of the 65 with normal pituitary function, 
23 developed a new pituitary axis deficit (Supplementary 
table I). Overall, 46% (16/35) males with normal gonadal 
function pre-SRS developed hypogonadism, 26% (21/81) 
of euthyroid patients developed new thyroid deficiency 
and 19% (15/77) with normal corticotroph function devel-
oped new cortisol deficiency after SRS (Fig. 3). At 4 and 
20 years, 25% and 50% of the cohort had developed a new 
axis deficit, respectively. The overall prevalence of pituitary 
dysfunction (all cause) in this cohort was 63% (66/104) at 
last follow up. Time for 25% of the population to develop 
hypogonadism (males only), hypothyroidism, and hypocor-
tisolism was 5, 12, and 21 years, respectively. New onset of 
hypopituitarism occurred as late as 16-, 20-, and 21.2-years 
post SRS in the gonadal, thyrotroph, and corticotroph axes, 
respectively. There was an association between the sever-
ity (axes affected) and the number of interventions received 
(p = 0.007) (Supplementary Table I). A breakdown of pre 
and post SRS anterior pituitary deficits is provided in Sup-
plementary Table II.
Table 3  Analysis of non-endocrine morbidity of stereotactic radiosurgery (SRS)
## Of those receiving a single MRI-guided SRS treatment and no fractionated radiotherapy there were no cases of visual loss and there were 2 
cases of ophthalmoplegia
@ Incidence of any non-endocrine complication per patient year was 0.002 (26/13,937)
Deficit Complication rate for 




Median onset Complication rate 
for MRI-guided 




SRS; no previous 
RT (n = 68) (October 
1993–2015)
Factors associated with 
increased risk
Loss of visual acuity 5.8% (6)## 12 months (6–106) 2.2% (2) 0%  > 1 radiation treatment 
(p = 0.04)
Ophthalmoplegia 6.7% (7)## 24 months (2–78) 7.7% (7) 2.9% (2)  > 1 radiation treatment 
(p = 0.03)
Trigeminal Neuralgia 1% (1) 4 days 1.1% (1) 0 N/A
Stroke/TIA 2.9% (3) 83.5 months (47–105) 3.3% (3) 2.9% (2) Similar incidence to 
that expected for 
age-sex matched 
population
Need for further inter-
vention—Surgery
5.8% (6) 18 (8–68) 3.3% (3) 2.9% (2)
Need for further inter-
vention—Radiation




Nine patients required further intervention post SRS, due to 
inadequate GH control (as determined by regional endocri-
nologists); three underwent fractionated radiotherapy, six 
underwent transsphenoidal surgery (Table 2).
Discussion
We have demonstrated that SRS for acromegaly does not 
increase the risk of stroke when compared to control popu-
lations that were matched for both age and sex, and impor-
tantly by actual year of the event. To the best of our knowl-
edge, such an analysis has not been done before for SRS 
to the pituitary region, where stroke risk due to disease is 
hard to decipher from treatment-related stroke risk. In other 
series, weighted mean risk of stroke in an acromegaly popu-
lation post SRS is 0.3% (with a range across series of 0% to 
5.7%) [10]. Of note the median dose was 21 Gy across these 
centres, lower than what we report here. In the same system-
atic review [10], the stroke rate for fractionated stereotactic 
radiotherapy was 4.5% (range across series 0% to 9%) where 
median dose was 49 Gy. Simple comparison of the stroke 
rate following SRS and RT is, however, confounded by the 
heterogenicity of treatment received and the background 
stroke risk of patients with uncontrolled growth hormone 
levels and the sequelae of acromegaly. There is likely both 
an observational and publication bias in the reporting of 
stroke in the literature. To avoid some of these confounders, 
our study sought to compare our SRS acromegaly cohort 
with that of similar age-matched populations by actual year. 
Whilst our data is specific for patients with acromegaly, we 
believe that it is likely that the observations will be general-
isable to other patients with pituitary tumours.
Radiation therapy is thought to work not only by stopping 
tumour cell mitosis, but also through thrombo-obliterative 
and vascular changes. This mechanism explains its use in 
arteriovenous malformations and benign tumours, e.g. men-
ingiomas [21]. Radiation can cause apoptosis and subse-
quent endothelial loss. Local inflammatory response and 
upregulation of hypoxia-related genes can lead to vascular 
injury, atherosclerosis and thromboembolism [26]. These 
data emphasise the potential issues pertaining to normal 
Fig. 3  Onset of anterior pituitary axis deficit in our cohort over time. 
Seven patients had deficits in all 3 axes prior to stereotactic radiosur-
gery (SRS). Dotted lines represent 95% confidence intervals. a Inci-
dence of hypopituitarism post SRS (excluding patients with panhypo-
pituitarism pre-SRS) (34/97) b Incidence of testosterone replacement 
post SRS (16/35) c Incidence of thyroxine replacement therapy post-




tissue receiving excess radiation and the need for our analy-
ses here.
Historically, visual loss was observed where high doses 
reached the optic nerves [14, 15, 27]. Improvement in imag-
ing quality and radiation delivery now ensures that the dose 
to the optic nerve can be kept less than 8 Gy, as recom-
mended [4, 9]. Where tumour proximity would mean a 
higher dose being delivered to the optic nerve with SRS, 
surgery before SRS may be used to debulk the tumour and 
allow sufficient distance between tumour and optic apparatus 
for SRS to be safely administered, but if this is not possi-
ble fractionated radiation is preferred [4]. In our cohort, six 
patients developed loss of visual acuity at a median delay 
of 12 months; four of whom had > 1 radiation treatment, 
and four had now outdated CT-guided SRS; all patients had 
one or both of these risk factors (Table 2). In contrast there 
were no cases of visual loss in those who received only a 
single MRI-guided SRS treatment and no fractionated radio-
therapy. Multiple treatments of any type, and regardless of 
order, appear to be associated with increased complication 
incidence (Supplementary table I). Rates of visual loss from 
SRS are reported to vary between centre, case selection and 
tumour location [10, 14, 15, 27]. It has been suggested that 
the tolerable absolute dose to the optic chiasm and volume 
treated varies between patients, as this may be altered by 
patient age, vascular comorbidities, previous treatments, 
and degree of nerve compression [10]. Nevertheless, it is 
not possible to offer firm guidance on dose reduction other 
than stating that the risk of visual loss appears greater with 
previous optic nerve irradiation and keeping the dose to the 
chiasm < 8 Gy appears to be safe for single treatments.
Ophthalmoplegia is a known complication of SRS when 
used on tumours invading the cavernous sinus. Literature 
reports incidence of new cranial neuropathies in either the 
oculomotor, trochlear, trigeminal nerves of 1.3% (21/1621), 
of which 50% were transient [28]. A more recent systematic 
review calculated a weighted mean for cranial nerve deficit 
of 0.45% (with rates per centre ranging from 0 to 5.7%) [10]. 
These are not seen where SRS dose is kept < 20 Gy [10] or 
where eloquent targets are kept below their threshold lev-
els. Prior data from our unit has shown an ophthalmoplegia 
incidence of 1.1% for patients undergoing lower dose treat-
ment (20 Gy) for skull-base meningiomas (of which 52% 
of tumours involved the cavernous sinus) [21]. The wide 
range of peripheral doses given (defined by the 50% isodose 
contour) doesn’t equate directly to dose reaching cranial 
nerves or pituitary gland, which is dependent on the precise 
dosimetry planning. Higher radiation doses are associated 
with more complications but the threshold of radiation that 
is associated with nerve damage is variable, with sensory 
nerves appearing to be more susceptible. In our acromegaly 
cohort, 81% (84/104) had cavernous sinus invasion, the 
mean dose was 28 Gy, and the incidence of ophthalmoplegia 
in those with cavernous sinus targeting was 8% (7/84). All 
seven cases of opthalmoplegia were MRI-guided, had had 
prior TSS, and had cavernous sinus invasion. Five of these 
seven had prior fractionated radiotherapy. Thus, ophthalmo-
plegia is a risk for patients undergoing SRS and who have 
cavernous sinus invasion, especially if there has been prior 
radiation therapy. Unfortunately, the method of data collec-
tion did not allow us to confirm whether the opthalmoplegia 
was transitory or permanent; other series’ suggest the half 
are transient. Careful counselling of patients is needed about 
this potential complication ahead of treatment.
Higher complication rates to vision and more severe 
hypopituitarism are seen in patients receiving two radia-
tion treatments [27, 29]. It has been hypothesised that 40% 
[18]–50% [29] of the original radiation dose should be 
included in future dose calculations to the optic nerve. Our 
data demonstrate that where a single treatment of SRS is 
used (without concomitant fractionated radiotherapy), then 
lower complications rates to visual acuity and ophthalmo-
plegia are seen (p < 0.05) (Supplementary table I).
Hypopituitarism
Hypopituitarism is a recognised side effect of RT, in the 
treatment of Acromegaly. Using fractionated radiotherapy, 
progressive hypopituitarism develops with 50–80% affected 
at 10 years mean follow-up [9]. Hypopituitarism of any 
type before treatment appears to increase the risk of subse-
quent hypopituitarism after fractionated radiotherapy [9]. 
Increased dose received by the pituitary stalk [30], cavern-
ous sinus invasion [31], marginal (50%) dose (> 25 Gy) and 
tumour volume (> 2.5 ml) are associated with higher rates 
of hypopituitarism [14]. Our data found the total number of 
interventions of any type was also associated with degree of 
hypopituitarism (p < 0.01; Supplementary table I). Overall 
it appears that hypopituitarism levels are lower with SRS 
where rates of 10–50% at 5 years have been described [10, 
11, 14]. However, the reported mean follow-up for those 
undergoing SRS is shorter than the follow-up period doc-
umented for fractionated radiation. The Virginia group 
published their SRS follow-up data (median 160 months; 
range 60–278 months) and demonstrated increased hypopi-
tuitarism with time [31]. In their cohort of 60 patients (24 
Acromegaly: 36 Cushings Disease), the 10-year incidence 
of new hypopituitarism was 53.3% [31]. In our series 36% 
of our pre-SRS eupituitary cohort (n = 60) developed new 
hypopituitarism at median follow up of 114 months (mean 
143). Our data suggests that SRS causes less hypopituitarism 
than fractionated radiation. However previous studies may 
have underreported the incidence of hypopituitarism, as it 
increases with length of follow-up. These data emphasise 





This is a large series with the longest recorded mean 
follow-up. We have carefully calculated the standardised 
incidence ratio (SIR) of stroke risk. Limitations include 
the retrospective nature of the study, reliance on recorded 
data and questionnaires, both of which introduce selec-
tion and recall bias. We are unable to report on growth 
hormone control due to the regional testing and manage-
ment of Acromegaly in the UK. This is further limited by 
the regional variance seen in both testing methodology 
and frequency. We used active prescriptions for hormone 
replacement as a proxy for a biochemical diagnosis of 
hypopituitarism. While reflecting real-world medicine, our 
methodology may fail to capture sub-clinical or delayed 
hypopituitarism [32].
The design of this study and associated analyses are 
subject to confounding and our sample size was con-
strained by the number of patients having undergone SRS 
at our site. Nevertheless, the small number of SRS pro-
cedures undertaken and the long term follow-up means 
any prospective study would be a prohibitively long and 
expensive to address this question.
The Standardised Incidence Ratio (SIR) for cardiovas-
cular accidents was derived by comparing the incidence 
against age/sex-matched data from two separate cohort stud-
ies, allowing us to demonstrate some robustness against the 
choice of reference population. Neither cohort contained 
details of other risk factors, and our SIR will be overesti-
mated if patients undergoing SRS also have more risk factors 
which predispose to stroke (e.g. prior surgical procedures, co-
morbidities). We are not aware of any data sets that contain 
extensive details on risk factors; moreover, if such nuanced 
data were to exist it would likely be far smaller than the two 
reference cohorts used here, meaning any gain in accuracy 
would come at a risk of a loss of precision. In absolute terms, 
the sparsity of stroke incidence (estimated as 3 per 1000 per-
son-years) means it is unlikely the conclusions would change 
appreciably, were other reference populations used.
Conclusion
This is the longest reported follow-up of any cohort of 
patients with acromegaly treated by gamma knife, specifi-
cally assessing morbidity and mortality. Our data show 
that there is no excess risk of stroke following SRS for 
acromegaly, and we believe that it is likely that this obser-
vation is generalisable to SRS for other pituitary tumours. 
Morbidity is associated with the number of interventions 
required to achieve GH control. When using MRI-planning 
and single SRS treatments, with no other form of radiation 
treatment, we found no risk for decreased visual acuity. 
Treating tumours in the cavernous sinus, especially where 
more than one radiation treatment is given, carries greater 
risk of opthalmoplegia and patients should be counselled 
about this potential effect. While the rate of hypopituita-
rism increases with time, it appears less prevalent than 
after fractionated radiotherapy. However patients having 
received SRS to the pituitary do need long term surveil-
lance and testing for this.
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